皮肤癌诊断服务商Castle Biosciences, Inc. (CSTL)股价在周四的盘后交易中大涨5.53%,再次引发关注。
这一涨幅主要是受该公司最新公布的利好第三季度财务业绩所推动。数据显示,Castle Biosciences在本季度业绩大幅超出市场预期,调整后每股盈利为0.08美元,高于去年同期的亏损0.26美元,并大大超出分析师预期的0.06美元亏损。
营收方面,公司本季度营收同比增长39.5%至8,578万美元,也超过了华尔街分析师此前7,984万美元的预期。在如此喜人的业绩表现后,随着投资者对该公司长期前景信心的增强,Castle Biosciences股价在周四盘后飙升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.